Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
great news - it seems but nothing happens except downward pressure.
it is tough to deal with.
IMO the covid stuff is basically over..
COVID is over.
Omnicron is a zero..
focus on the pain/cancer treatment in pipe line.
good luck ..we need it.
warrants leading the way and foretelling the future..
volume doubled in five minutes.. interesting...
NEWS ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles
Immix Biopharma, Inc. (NASDAQ:IMMX)
100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial
IMX-110 is in clinical development as a monotherapy for soft tissue sarcoma (STS), a $3 billion market expected to grow to $6.5 billion by 2030
A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b83a7ede-262b-4777-a2f9-beb13ee761bc
LOS ANGELES, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial. Historically, 43-67% of patients have completed planned treatment cycles with approved drugs used to treat soft tissue sarcoma (STS) according to Demetri et al., 2016, and Schöffski et al., 2016. Completion of planned treatment cycles refers to lack of drug-related interruptions (cycle delays, dose reductions, or dose interruptions due to drug toxicity).
“With standard treatments widely used today, cancer patients face a long list of drug-related debilitating side-effects that cause treatment delays, dose reductions, or dose interruptions due to toxicity, interfering with the ability to treat them effectively,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “In this interim clinical trial update, we are thrilled to report that IMX-110 has been well tolerated. We believe that IMX-110 could become a potentially attractive option to improve the patient experience in oncology in the future.”
The U.S. Food and Drug Administration (“FDA”) has approved orphan drug designation (“ODD”) for IMX-110 for the treatment of soft tissue sarcoma. The FDA has already approved rare pediatric disease (“RPD”) designation to IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma.
warrants moving like crazy... fortelling the future...
make sure you satisfy that margin call in a couple days...
yes it has a shot today over 90 will be halt #1..
on the verge of a vol increase/start of a squeeze and 1st Halt...
and drinking Beer and staring at all those magnets..
DWAC beginning very early squeeze here..
85 + more volume will equal greater squeeze..
starting to SQUUEEZZE.. gaining momentum.
diamond hands..
that breaker may get tripped somewhere over 80-85..
BBIG halted at $5.31
200 day MA is 4.15 the volume is amazing. this is going to blow...
75 up next...
NEWS ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study
IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice study
IMX-110 response rate surpassed standard of care doxorubicin’s response rate of 0% after 1 cycle of treatment in the same study
IMX-110 is in clinical development for STS, a $3 billion market expected to grow to $6.5 billion by 2030
LOS ANGELES, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study. The responses were assessed by RECIST 1.1 criteria applied to mice, with progression assessed after one cycle of treatment in a study funded by ImmixBio and conducted by a major STS oncology treatment center.
“We strive to test our drug candidates in the most realistic, challenging animal models available,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “We are thrilled to see that in this first-line-therapy resistant STS model that IMX-110 showed significant activity. We believe this study is a preview of what our SMARxT Platform generating Tissue-Specific Therapeutics can do, a distinct alternative to the traditional ‘single target, single mutation’ development model.”
The U.S. Food and Drug Administration (“FDA”) has approved orphan drug designation (“ODD”) for IMX-110 for the treatment of soft tissue sarcoma. The FDA has already approved rare pediatric disease (“RPD”) designation to IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma.
ImmixBio recently shared IMX-110 clinical data across multiple STS subtypes in several heavily pretreated patients demonstrating median progression-free survival (PFS) of 4 months with zero drug-related severe adverse events and zero dose interruptions due to toxicity. The data can be viewed in the Immix Biopharma Corporate Presentation at http://www.immixbio.com/pres
Soft tissue sarcoma is a cancer that begins in the tissues that connect, support, and surround body structures. The global STS market is estimated to reach approximately $6.5 billion by 2030 from the estimated $2.9 billion in 2019. Globally, there are roughly 116,000 new cases of STSs each year, of which 21,500 are in the European Union and 40,500 are in China. According to the American Cancer Society, there were roughly 13,000 new cases of STS in the United States during 2020. Approximately 160,000 people live with soft tissue cancers in the United States.
Thank you again..Your posts are bordering on the Legendary here.
they are like a lighthouse beacon flashing in a dark stormy sea..
despite needing a Davinci code to decipher.. I am starting to get the jist of it..
Cashclan. I enjoy your posts and they are interesting as always(from what I can decipher) but no one really understands what you are saying (and I am good in math)....
Not sure if you are posting like that on purpose but maybe try to have a short 1 line translation at the bottom of your DWAC/CFVI posts.
it would help greatly...
thank you
we are so far from getting relisted that I can't even imagine what would be needed to get off the grays. 4 years of financials, atty letters..etc..just to start...
good synopsis .. Naked shares all day long..
question have you ever seen 100x trade of the float though on anything?
making a move now... could be another halt over HOD. this is a low float low market cap stock .. no reason you cant see 50-100 in short order..
IMMX small market cap 50 mill ish..
proprietary drug for all cancers that incorporates an AI dispensing system that has shown to prolong life greatly without the Chemo side effects.
so there you have it...
Immix Biopharma's stock rockets after pediatric cancer treatment granted RPD by the FDA
Shares of Immix Biopharma Inc. IMMX, 110.33% rocketed 66.0% in premarket trading Monday, after the biopharmaceutical company said its IMX-110 was granted Rare Pediatric Disease (RPD) designation by the Food and Drug Administration for the threatment of pediatric cancer. The company said IMX-110 is current being evaluated in a Phase 1b/2a clinical trial. The company said if a New Drug Application (NDA) is approved, the company could be eligible to receiver a Priority Review Voucher (PRV) that can be redeemed to obtain priority review for any subsequent marketing application. "We are pleased by FDA's acknowledgment of the urgent need for a safe and effective treatment for children with this devastating disease," said Immix Chief Executive Ilya Rachman. "We are encouraged by our Phase 1b/2a clinical data in soft tissue sarcoma." The rally in Immix's stock, which went public on Dec. 16
Not too shabby news today!
Immix Biopharma, Inc. Announces Pricing of Initial Public Offering
LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $21,000,000 before deducting underwriting discounts, commissions and offering expenses. In addition, ImmixBio has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares of common stock solely to cover over-allotments.
The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “IMMX” on December 16, 2021. The offering is expected to close on December 20, 2021, subject to satisfaction of customary closing conditions.
The net proceeds from the initial public offering will be used to fund a planned IMX-110 Phase 2a clinical trial in soft tissue sarcoma and IMX-110 + tislelizumab Phase 1b combination trial, for IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease), and for working capital and other general corporate purposes.
ThinkEquity is acting as the sole book-running manager for the offering.
The registration statement on Form S-1 (file No. 333-259591) relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission and became effective on December 15, 2021. A final prospectus related to the proposed offering will be filed and made available on the SEC’s website at https://www.sec.gov/. The offering is being made only by means of a prospectus. Electronic copies of the final prospectus may be obtained, when available, from ThinkEquity, 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 and by email at prospectus@think-equity.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ImmixBio
ImmixBioTM is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-SpecificTM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and immuno-dysregulation. In addition to oncology, our pipeline includes Tissue-Specific BiologicTM candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Learn more at www.immixbio.com.
I still don't see the pump...
just getting back into it's previous trading range from being untradable for a few months and.... under super light volume..
whoa.. that changes things.. LOL
welcome back dude..
where is the pump?
Where o Where are all my buddies?
seems like they vanish when RMHB riseth up...
how did you buy at .000... ?
inquiring minds want to know
wow
you are a legend dude.!
congrats on that one
can we get a translation of that please?
thank you
Ahh my buddy is here..
thank goodness..
Well, as I know how much you are a huge fan of CBD and CBD products- I feel the purpose is to have a calmer energy boost rather than a sugar induced super boost like the current energy drinks .
Celsius - to me is the best for something close to this right now but still has some jittery effect.
Bang is probably the most potent and is ultra jittery.
I have had 2 Rocket highs thus far and I really liked them. Didn't feel the jitters but my sample size was too low... more testing will be needed..
Cheers
New CBD life- Rocket high Commercial
pretty Killer - I was surprised at how good it is..
https://www.linkedin.com/posts/conqrmx_rocket-high-crea-tu-propia-realidad-activity-6863624297546702848-H2Ys/
not quite.. I sold 60% but rebought the ones I sold at 100-120.. so we are in for the long haul.. should test 70 shortly..
Still here.. watching some more Ducks and spending more of my DWA%W winnings on crypto , a new fishing boat and such..
As far as RMHB? well up 250% today! lol take that ..
all kidding aside (The RMHB part) nothing is going to happen until the filings are caught up .. it is a dead zone till that time.
enjoy your weekend!
dont panic big boy.. major gap to fill from 1.05 to 1.40 from May..
it is inevitable very soon..
enjoy!
Making a big move. Over 70 this will expode
how is that working out?
big gap to fill from 1.05-1.40 still from May... this would be 1st target area..